0001140361-17-019246.txt : 20170510 0001140361-17-019246.hdr.sgml : 20170510 20170510114858 ACCESSION NUMBER: 0001140361-17-019246 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170510 DATE AS OF CHANGE: 20170510 EFFECTIVENESS DATE: 20170510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HDL THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001569047 IRS NUMBER: 273015978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-270577 FILM NUMBER: 17829157 BUSINESS ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 BUSINESS PHONE: 772-453-2770 MAIL ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 D/A 1 primary_doc.xml X0707 D/A LIVE 0001569047 HDL THERAPEUTICS, INC. 601 21st Street Suite 300 Vero Beach FL FLORIDA 32960 772-453-2770 DELAWARE None None Corporation true 2013 Michael Matin c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Bryan Brewer c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Dr. Brewer is the Chief Scientific Officer of the Issuer. Biotechnology Decline to Disclose 06b true 0001140361-16-079730 2016-08-05 true true true Series C Preferred Stock false 0 None None Frontier Solutions, LLC 136102 9 East Franklin Street Richmond VA VIRGINIA 23219 AL ALABAMA AR ARKANSAS AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA KY KENTUCKY LA LOUISIANA MA MASSACHUSETTS MD MARYLAND MN MINNESOTA NC NORTH CAROLINA NJ NEW JERSEY NY NEW YORK OH OHIO OR OREGON PA PENNSYLVANIA SC SOUTH CAROLINA TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WY WYOMING false None None Morgan Stanley & Co. LLC 8209 1585 Broadway New York NY NEW YORK 10036-8293 All States false 12000000 7195065 4804935 true 0 57 187730 true 0 Commissions have been and will be paid to the persons named in Item 12 for introductions to investors. 400000 true The gross proceeds from the offering will be used for working capital, some of which will be used to pay the salaries of related persons named in Item 3. false HDL THERAPEUTICS, INC. /s/ Michael Matin Michael Matin Chief Executive Officer of the Issuer 2017-05-10